1. Home
  2. USAU vs CMPX Comparison

USAU vs CMPX Comparison

Compare USAU & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Gold Corp.

USAU

U.S. Gold Corp.

HOLD

Current Price

$13.92

Market Cap

242.1M

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$0.97

Market Cap

203.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USAU
CMPX
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.1M
203.5M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
USAU
CMPX
Price
$13.92
$0.97
Analyst Decision
Strong Buy
Buy
Analyst Count
3
15
Target Price
★ $26.50
$5.45
AVG Volume (30 Days)
132.1K
★ 5.6M
Earning Date
09-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.11
N/A
EPS
N/A
★ N/A
Revenue
★ $17,402,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.23
$0.89
52 Week High
$23.72
$6.88

Technical Indicators

Market Signals
Indicator
USAU
CMPX
Relative Strength Index (RSI) 34.74 22.99
Support Level $13.53 N/A
Resistance Level $16.23 $2.08
Average True Range (ATR) 0.48 0.10
MACD -0.18 -0.02
Stochastic Oscillator 9.14 10.29

Price Performance

Historical Comparison
USAU
CMPX

About USAU U.S. Gold Corp.

U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: